ATE405282T1 - Verwendung von il-13 inhibitoren zur behandlung von tumoren - Google Patents

Verwendung von il-13 inhibitoren zur behandlung von tumoren

Info

Publication number
ATE405282T1
ATE405282T1 AT01989341T AT01989341T ATE405282T1 AT E405282 T1 ATE405282 T1 AT E405282T1 AT 01989341 T AT01989341 T AT 01989341T AT 01989341 T AT01989341 T AT 01989341T AT E405282 T1 ATE405282 T1 AT E405282T1
Authority
AT
Austria
Prior art keywords
subject
inhibitors
treat tumors
inhibitor
response
Prior art date
Application number
AT01989341T
Other languages
German (de)
English (en)
Inventor
Jay Berzofsky
Masaki Terabe
Debra Donaldson
So Matsui
Nancy Noben-Trauth
William Paul
Original Assignee
Genetics Inst
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26981351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE405282(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst, Us Gov Health & Human Serv filed Critical Genetics Inst
Application granted granted Critical
Publication of ATE405282T1 publication Critical patent/ATE405282T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT01989341T 2000-10-20 2001-10-22 Verwendung von il-13 inhibitoren zur behandlung von tumoren ATE405282T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69360000A 2000-10-20 2000-10-20
US31818501P 2001-09-07 2001-09-07

Publications (1)

Publication Number Publication Date
ATE405282T1 true ATE405282T1 (de) 2008-09-15

Family

ID=26981351

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01989341T ATE405282T1 (de) 2000-10-20 2001-10-22 Verwendung von il-13 inhibitoren zur behandlung von tumoren

Country Status (8)

Country Link
EP (2) EP1333850B1 (https=)
JP (2) JP2004537500A (https=)
AT (1) ATE405282T1 (https=)
AU (1) AU2002243443A1 (https=)
DE (1) DE60135481D1 (https=)
DK (1) DK1333850T3 (https=)
ES (1) ES2311558T3 (https=)
WO (1) WO2002055100A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050069546A1 (en) * 2003-09-30 2005-03-31 Yaron Ilan Educated NKT cells and their uses in the treatment of immune-related disorders
PL3718564T3 (pl) * 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
US20050266005A1 (en) * 2004-02-27 2005-12-01 Heavner George A Methods and compositions for treating IL-3 related pathologies
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
EP1824886B1 (en) 2004-11-17 2010-12-22 Amgen Inc. Fully human monoclonal antibodies to il-13
ES2523172T3 (es) * 2005-02-04 2014-11-21 Survac Aps Vacuna de péptido de survivina
JP2010502224A (ja) 2006-09-08 2010-01-28 アボット・ラボラトリーズ インターロイキン１３結合タンパク質
WO2011003138A1 (en) * 2009-07-06 2011-01-13 The Australian National University Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor
RU2578468C2 (ru) 2010-12-16 2016-03-27 Дженентек, Инк. Способы диагностики и лечения, связанные с ингибированием th2
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
CN120904322A (zh) 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
WO2015125652A1 (ja) * 2014-02-21 2015-08-27 Ｉｄａｃセラノスティクス株式会社 固形がんの治療剤
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
TW202509218A (zh) * 2023-07-12 2025-03-01 亨利傑克森軍方醫學基金會 用於抑制自然殺手細胞之組合物及方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294322B1 (en) 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1994004680A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Human interleukin-13
US20010053371A1 (en) * 1999-01-07 2001-12-20 Waldemar Debinski Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
JPH09150569A (ja) 1995-11-29 1997-06-10 Riso Kagaku Corp 色画像形成用シート
GB9625899D0 (en) * 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6013258A (en) 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
MXPA01006006A (es) * 1998-12-14 2004-08-12 Genetics Inst Cadena receptora de citocina.
MXPA01008142A (es) * 1999-02-10 2003-07-21 Welfide Corp Compuestos de amida, y uso medicinal de los mismos.
US6703360B2 (en) * 2000-04-07 2004-03-09 Heska Corporation Compositions and methods related to canine IgG and canine IL-13 receptors

Also Published As

Publication number Publication date
EP1333850A2 (en) 2003-08-13
JP2004537500A (ja) 2004-12-16
DK1333850T3 (da) 2008-12-01
WO2002055100A9 (en) 2006-05-11
AU2002243443A1 (en) 2002-07-24
EP1333850B1 (en) 2008-08-20
ES2311558T3 (es) 2009-02-16
WO2002055100A3 (en) 2003-03-27
JP2009046512A (ja) 2009-03-05
AU2002243443A8 (en) 2005-10-13
EP2027867A1 (en) 2009-02-25
WO2002055100A2 (en) 2002-07-18
DE60135481D1 (de) 2008-10-02

Similar Documents

Publication Publication Date Title
ATE405282T1 (de) Verwendung von il-13 inhibitoren zur behandlung von tumoren
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ID26620A (id) Penghambatan kinase raf yang menggunakan urea-urea heterosiklik yang disubstitusi
NO933126D0 (no) Loeselige ligander for cd40
DK1064027T3 (da) APO-2 Ligand-anti-her-2-antistofsynergier
DE602007012677D1 (de) Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen
AU2483000A (en) Treatment of asthma with mek inhibitors
ATE453707T1 (de) Verfahren zur isolierung von mesenchymalen stammzellen des haarfollikels
NZ524559A (en) 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE326209T1 (de) Verminderung des haarwuchses
ATE531388T1 (de) Verwendung von anti-alpha5beta1-antikörpern zur hemmung der krebszellproliferation
DK1401413T3 (da) Anvendelse af tyrosinkinaseinhibitorer til behandling af allergiske sygdomme
DE60026010D1 (de) Substituierte stilbene mit gefässschädigender aktivität
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
EE200200337A (et) Uued ühendid ning nende kasutamine
NO20002218D0 (no) Anvendelse av mirtazepin for behandling av søvnapne
DK1485345T3 (da) Urokinaseinhibitorer, deres fremstilling og anvendelse
ATE424217T1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
WO2002067652A3 (en) Novel mutilple shoot proliferation and regeneration system for plants
ATE253930T1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)- aktivierungsweges
DE60231896D1 (de) Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
ATE294811T1 (de) Antisense-modulation von x-verbundenen inhibitoren der apoptosis-expression
ATE300944T1 (de) Verwendung von substituierten distamycin- acryloylderivaten zur behandlung von tumoren die mit erhöhten glutathion-spiegeln zusammenhängen
DE60117783D1 (de) Naphthamidin-urokinasinhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties